Roche news - the latest biotech news from Labiotech.eu

Roche and Alnylam to work on RNAi therapeutic to treat hypertension

Jim Cornall — Tue, 25 Jul 2023 09:00:00 +0000

Roche has announced a partnership with Alnylam to develop and commercialize zilebesiran, an investigational RNAi therapeutic currently in phase 2 for the treatment of hypertension. Hypertension affects more than 1.2 billion adults worldwide and is the main, independent, preventable risk factor for death and disability, with approximately 80% of the adults with hypertension worldwide not […]

The post Roche and Alnylam to work on RNAi therapeutic to treat hypertension appeared first on Labiotech.eu.

© Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.

Seven pharma companies form alliance to prepare for future pandemics

Jim Cornall — Thu, 20 Jul 2023 14:00:00 +0000

Seven pharmaceutical companies have established the INTREPID Alliance with the goal of accelerating progress in discovery and development of new antiviral treatments for future pandemics. The seven companies are AbbVie, Amgen, Gilead, Johnson & Johnson, Novartis, Roche and Takeda. The INTREPID alliance creation is in support of the 100 Days Mission, which seeks to have […]

The post Seven pharma companies form alliance to prepare for future pandemics appeared first on Labiotech.eu.

FDA approves Genentech’s lymphoma drug

Jim Cornall — Thu, 20 Apr 2023 10:59:45 +0000

Genentech, a member of the Roche Group, has announced the U.S. Food and Drug Administration (FDA) has approved Polivy (polatuzumab vedotin-piiq) in combination with Rituxan (rituximab), cyclophosphamide, doxorubicin and prednisone (R-CHP). The approval covers the treatment of adult patients who have previously untreated diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS) or high-grade B-cell […]

The post FDA approves Genentech’s lymphoma drug appeared first on Labiotech.eu.

Sysnav and Roche partner on movement tracking technology

Jim Cornall — Thu, 26 Jan 2023 08:39:13 +0000

Sysnav Healthcare and Roche have partnered to develop industry standard outcome measurements in diseases associated with movement impairments, as well as designing the next generation of wearable technology based on Sysnav’s technology. Patients living with a neuromuscular disorder often suffer from movement impairments that fundamentally impact their daily life. Reliable, objective measurements of a patient’s […]

The post Sysnav and Roche partner on movement tracking technology appeared first on Labiotech.eu.

Cell and gene therapies gain momentum in Basel

External Contributor — Tue, 17 Jan 2023 10:52:06 +0000

Companies specializing in the research and development of innovative cell and gene therapies continue to spring up all around the globe, and a growing number are choosing the Swiss city of Basel as their base. These companies are taking advantage of the talent pool, academic institutions and investors that the area has to offer, culturing […]

The post Cell and gene therapies gain momentum in Basel appeared first on Labiotech.eu.

FDA clears insulin pen medical device

Jim Cornall — Wed, 07 Dec 2022 12:39:21 +0000

BIOCORP, a French company specialized in the design, development, and manufacturing of innovative medical devices, has received 510(K) clearance from the U.S. Food & Drug Administration (FDA) to market Mallya, its smart medical device that connects insulin pens. Eric Dessertenne, CEO of BIOCORP, said: “This approval is a major achievement for BIOCORP and all of […]

The post FDA clears insulin pen medical device appeared first on Labiotech.eu.

Jnana Therapeutics raises $107M for PKU program and announces new Roche partnership

Jim Cornall — Tue, 15 Nov 2022 16:53:21 +0000

Jnana Therapeutics has entered into a second collaboration and license agreement with Roche for the discovery of small molecule drugs for the treatment of cancer, immune-mediated and neurological diseases. The collaboration covers multiple targets from a diverse range of target classes to address diseases with high unmet need. The company also announced the close of […]

The post Jnana Therapeutics raises $107M for PKU program and announces new Roche partnership appeared first on Labiotech.eu.

Needle-free diabetes care: 7 devices that painlessly monitor blood sugar

Clara Rodríguez Fernández — Fri, 07 Oct 2022 12:00:46 +0000

Will the daily routine of finger pricking to monitor blood sugar levels finally come to an end for the millions living with diabetes? Diabetes affects over 537 million adults worldwide. People with diabetes have to test their blood sugar levels several times a day, usually by pricking their finger with a lancet. This can be […]

The post Needle-free diabetes care: 7 devices that painlessly monitor blood sugar appeared first on Labiotech.eu.

Roche launches next-generation SARS-CoV-2 Rapid Antibody Test

Jim Cornall — Mon, 03 Oct 2022 09:17:02 +0000

Roche has launched the SARS-CoV-2 Rapid Antibody Test 2.0 in markets accepting the CE Mark. The test is the next generation of Roche’s existing SARS-CoV-2 Rapid Antibody Test, which launched in July 2020. The SARS-CoV-2 Rapid Antibody Test 2.0 offers broader use than its original configuration, which focused on recovered patients, to now include vaccinated […]

The post Roche launches next-generation SARS-CoV-2 Rapid Antibody Test appeared first on Labiotech.eu.

Ghana first to benefit from Roche partnership with Jhpiego to improve cervical and breast cancer outcomes for women

Jim Cornall — Fri, 16 Sep 2022 12:02:17 +0000

Roche has signed a memorandum of understanding (MoU) with the Johns Hopkins Program for International Education in Gynecology and Obstetrics (Jhpiego) to improve cervical and breast cancer outcomes in resource-constrained countries. Breast cancer is the most diagnosed cancer and the cause of the most cancer-related deaths in women. Similarly, cervical cancer is the fourth most […]

The post Ghana first to benefit from Roche partnership with Jhpiego to improve cervical and breast cancer outcomes for women appeared first on Labiotech.eu.

New research boosts Nordic Bioscience’s PRO-C6 as biomarker assay for trial enrichment in HFpEF

Jim Cornall — Thu, 15 Sep 2022 09:23:25 +0000

The New England Journal of Medicine Evidence (NEJME) has published research that further establishes and positions Nordic Bioscience’s extracellular matrix (ECM) biomarker, PRO-C6, as a potential next-generation biomarker for trial enrichment in patients with heart failure with preserved ejection fraction (HFpEF). The paper is entitled “Endotrophin, a collagen VI formation-derived peptide, in Heart Failure.” The […]

The post New research boosts Nordic Bioscience’s PRO-C6 as biomarker assay for trial enrichment in HFpEF appeared first on Labiotech.eu.

Roche launches COVID-19 test to detect emerging variant of interest

Jim Cornall — Mon, 22 Aug 2022 09:07:41 +0000

Roche and its subsidiary TIB Molbiol have developed a COVID-19 test for researchers that detects and differentiates the latest sub-variant of interest BA.2.75. The test specifically targets two of the known unique mutations in BA.2.75, which allows clear differentiation against other notable subvariants. “Roche is pleased to have developed a test for researchers that provides […]

The post Roche launches COVID-19 test to detect emerging variant of interest appeared first on Labiotech.eu.

Roche announces influenza drug approval and new COVID test

Jim Cornall — Mon, 15 Aug 2022 08:47:16 +0000

Roche has announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for Xofluza (baloxavir marboxil) for the treatment of acute uncomplicated influenza in otherwise healthy children aged five to less than 12 years of age who have been symptomatic for no more than 48 hours. This marks […]

The post Roche announces influenza drug approval and new COVID test appeared first on Labiotech.eu.

The Future of Diabetes Treatment: Is a Cure Possible?

Clara Rodríguez Fernández — Mon, 15 Nov 2021 12:25:00 +0000

Diabetes has become an epidemic, sentencing over 460 million people worldwide to lifelong medication. Science is striving to find a diabetes treatment that can cure this chronic disease, but how close are we? Diabetes is the major cause of blindness, kidney failure, heart attack, and stroke. It is estimated that the number of people affected […]

The post The Future of Diabetes Treatment: Is a Cure Possible? appeared first on Labiotech.eu.

EMA Approvals for Multiple Sclerosis Highlight Treatment Shortfalls

Jonathan Smith — Tue, 27 Apr 2021 10:20:40 +0000

While the EU saw rapid-fire approvals in the multiple sclerosis space last month, the innovations centered mostly on improving existing approaches. Which areas of multiple sclerosis treatment need more options? At the end of March, the EMA made key decisions on three treatments for multiple sclerosis (MS), a chronic neurodegenerative disease affecting 2.5 million people […]

The post EMA Approvals for Multiple Sclerosis Highlight Treatment Shortfalls appeared first on Labiotech.eu.

Roche Confirms Pharma Appetite for Inflammatory Disease Treatments

Jonathan Smith — Fri, 25 Sep 2020 16:52:17 +0000

Roche’s acquisition of the Irish biotech Inflazome is a vote of confidence for emerging inflammatory disease drugs. How could other companies in the field benefit from this takeover? The inflammation process is essential for our survival, as it helps the body to clear up damage after injury. However, uncontrolled inflammation can also harm us, causing […]

The post Roche Confirms Pharma Appetite for Inflammatory Disease Treatments appeared first on Labiotech.eu.

European Project Launches to Tailor Autoimmune Disease Treatments

Jonathan Smith — Thu, 31 Oct 2019 14:11:19 +0000

Public and private organizations across Europe will pool their resources in an €80M project to discover biomarkers that can predict which patients will respond best to treatments for autoimmune diseases. The project is called Taxonomy, Treatments, Targets and Remission, or 3TR for short, and is funded by the EU’s Innovative Medicines Initiative for the next […]

The post European Project Launches to Tailor Autoimmune Disease Treatments appeared first on Labiotech.eu.

Why Clinical Trial Design Can Make or Break Your Company

Helen Albert — Thu, 23 May 2019 12:12:11 +0000

Andreas Wallnöfer spent over 20 years working on drug development at Roche before moving to BioMedPartners to apply his expertise to biotech investment. At our recent Labiotech Refresh event in Zurich, he explained why good clinical trial design can be key to a biotech’s success. Wallnöfer was one of the pioneers of ‘proof of concept’ […]

The post Why Clinical Trial Design Can Make or Break Your Company appeared first on Labiotech.eu.

AI Drug Discovery Company Raises €23M and Signs with Roche

Clara Rodríguez Fernández — Mon, 07 Jan 2019 15:00:48 +0000

Oxford-based Exscientia has closed a €23M ($26M) Series B round and announced a partnership with Roche worth up to €60M. Exscientia has developed an artificial intelligence platform to boost drug discovery in pharma and biotech. “We can reduce at least 4- to 5-fold the time and cost of drug discovery as compared to the industry […]

The post AI Drug Discovery Company Raises €23M and Signs with Roche appeared first on Labiotech.eu.

Are PD-1 and PD-L1 Checkpoint Inhibitors As Good As We Thought?

Clara Rodríguez Fernández — Mon, 09 Apr 2018 06:45:16 +0000

Checkpoint inhibitors, especially those targeting PD-1 and PD-L1, are exploding in popularity. But how much of it is hype? The pipelines of biotech and pharma are filling up with combination therapies for anti-PD-1 and PD-L1 antibodies. According to the Cancer Research Institute, there are now over 1,500 clinical trials testing the popular checkpoint inhibitors, a dramatical increase […]

The post Are PD-1 and PD-L1 Checkpoint Inhibitors As Good As We Thought? appeared first on Labiotech.eu.